Memantine for cognitive impairment in multiple sclerosis: A randomized placebo-controlled trial

Multiple Sclerosis

Volumn 16, Issue 6, 2010, Pages 715-723

  Lovera, J F ^a   Frohman, E ^b   Brown, T R ^c   Bandari, D ^d   Nguyen, L ^e   Yadav, V ^e   Stuve, O ^b   Karman, J ^e   Bogardus, K ^e   Heimburger, G ^e   Cua, L ^d   Remingon, G ^b   Fowler, J ^b   Monahan, T ^c   Kilcup, S ^c   Courtney, Y ^c   McAleenan, J ^c   Butler, K ^c   Wild, K ^e   Whitham, R ^e,f,g   Bourdette, D ^e,f,g   more..

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UT Southwestern   (United States)

^c Evergreen Neuroscience Institute and Medical Center   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f PORTLAND VA MEDICAL CENTER   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Attention; Cognition disorders; Memantine; Memory; Multiple sclerosis; Neuropsychological tests; Placebo; Randomized controlled trial

Indexed keywords

MEMANTINE; PLACEBO;

ADULT; AGED; AGITATION; ARTICLE; ATAXIA; CAREGIVER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERABILITY; FAMILY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MOOD DISORDER; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SELF REPORT; SIDE EFFECT; SOMNOLENCE; SPASTICITY; SPEECH DISORDER; TREATMENT RESPONSE; UNSTEADINESS; URINARY TRACT INFECTION; ADOLESCENT; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; PATIENT SELECTION; PSYCHOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; COGNITION DISORDERS; DEPRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 77953733410     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510367662     Document Type: Article

References (27)

1. Amato MP, Ponziani G., Amaducci L. Cognitive impairment in multiple sclerosis: a longitudinal study. Electroencephalogr Clin Neurophysiol Suppl 1999 ; 50: 465-468.
2. Rao SM Neuropsychology of multiple sclerosis: a critical review. J Clin Exp Neuropsychol 1986 ; 8: 503-542.
3. Christodoulou C., Melville P., Scherl WF, Macallister WS, Elkins LE, Krupp LB Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 2006 ; 245: 127-136.
4. Shaygannejad V., Janghorbani M., Ashtari F., Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci 2008 ; 35: 476-481.
5. Morrow SA, Kaushik T., Zarevics P., Erlanger D., Bear MF, Munschauer FE, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol 2009 ; 256: 1095-1102.
6. Geisler MW, Sliwinski M., Coyle PK, Masur DM, Doscher C., Krupp LB The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996 ; 53: 185-188.
7. Lovera J., Bagert B., Smoot K., Morris CD, Frank R., Bogardus K., et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 2007 ; 13: 376-385.
8. Srinivasan R., Sailasuta N., Hurd R., Nelson S., Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005 ; 128: 1016-1025.
9. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius HJ Memantine in moderate-to-severe Alzheimers disease. N Engl J Med 2003 ; 348: 1333-1341.
10. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 ; 291: 317-324.
11. Rao SM The Cognitive Function Study Group of the National Multiple Sclerosis Society. Medical College of Wisconsin.
12. Delis DC, Kramer JH, Kaplan E., Ober BA California Verbal Learning Test Manual, Second edn Adult Version. Psychological Corporation.
13. Spreen O., Strauss E. A Compendium of Neuropsychological Tests, First edn. Oxford University Press.
14. Delis DC Delis-Kaplan Executive Functional Scales (D-KEFS). Psychological Corporation.
15. Benedict R., Fischer J., Archibald C., Arnett P., Beatty W., Bobholz J., et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 2002 ; 16: 381-397.
16. Sullivan JJL, Edgley K., Dehoux E. A survey of multiple sclerosis. Part 1: perceived cognitive problems and compensatory strategy use. Can J Rehabil 1990 ; 4: 99-105.
17. Fisk JD, Ritvo PG, Ross L., Haase DA, Marrie TJ, Schlech WF Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994 ; 18 (Suppl 1). S79 - S83.
18. Krupp LB, LaRocca NG, Muir-Nash J., Steinberg AD The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989 ; 46: 1121-1123.
19. Beck AT, Steer RA Manual for the Beck Depression Inventory. Psychological Corporation.
20. Moran PJ, Mohr DC The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med 2005 ; 28: 35-41.
21. Benedict RH, Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 2006 ; 245: 67-72.
22. Cummings JL, Mega M., Gray K., Rosenberg-Thompson S., Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994 ; 44: 2308-2314.
23. Kang SJ, Choi SH, Lee BH, Jeong Y., Hahm DS, Han IW, et al. Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). J Geriatr Psychiatry Neurol 2004 ; 17: 32-35.
24. Lipton SA Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006 ; 5: 160-170.
25. Pitt D., Nagelmeier IE, Wilson HC, Raine CS Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003 ; 61: 1113-1120.
26. Werner P., Pitt D., Raine CS Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001 ; 50: 169-180.
27. Villoslada P., Arrondo G., Sepulcre J., Alegre M., Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009 ; 72: 1630-1633.